InflaRx N.V. (IFRX)

NASDAQ
2.580
+0.080(+3.20%)
After Hours
2.640
+0.060(+2.326%)
- Real-time Data
  • Volume:
    119,829
  • Bid/Ask:
    2.490/2.640
  • Day's Range:
    2.460 - 2.679

IFRX Overview

Prev. Close
2.5
Day's Range
2.46-2.679
Revenue
-
Open
2.48
52 wk Range
2.36-6.87
EPS
-1.33
Volume
119,829
Market Cap
114M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
229,235
P/E Ratio
-
Beta
0.46
1-Year Change
-47.67%
Shares Outstanding
44,186,279
Next Earnings Date
Aug 05, 2021
What is your sentiment on InflaRx N.V.?
or
Market is currently closed. Voting is open during market hours.

InflaRx N.V. News

InflaRx N.V. Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuySellSellStrong Sell
Technical IndicatorsNeutralSellStrong BuySellStrong Sell
SummaryNeutralNeutralNeutralSellStrong Sell

InflaRx N.V. Company Profile

InflaRx N.V. Company Profile

Employees
47

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Read More
  • good stock at 3?
    0
    • Getting out. They blew it. Atleast in the near term.
      1
      • how about now?
        0
    • Loading up again... 10+ coming
      0
      • Its a buy again...
        0
        • Boom!
          0
          • Big popComin
            0
            • Seeking Alpha claims InflaRx reports underwhelming data but Benzinga claims encouranging results. WTH.
              0
              • Please release some news. Weve been hearing about covid trials for weeks!
                0
                • you got what you asked for. They just released results.
                  0
                • I changed my mind! It was better without... :) but seriously, i think this sell off is overdone. If phase ll was poor (and i dont think it was) they wouldnt be continuing to phase lll
                  0
                • Jacob Castanon exactly!
                  0
              • yeeeeea hot mama!
                0
                • gooooo, underdog!
                  0
                  • will IFRX be the secret underdog?
                    0
                    • Acute pneumonia from old,Gawasaki-like symptoms from young.Both are caused by C5a complement.
                      0
                      • Great stock. Worth keeping for at least 3 yrs
                        0
                        • they are hiring a lot of medical personal, obviously company is expanding
                          0
                          • Boom the moon
                            0
                            • I'm pharmacy student. Take a good look at this company and their target. C5a has been a minor target of Anti-inflammation. But paradigm's gonna change after SARS Cov 2
                              0
                              • worth sitting on
                                0
                                • with this small market cap this is very easy to be swollen by a giant pharma, at a great premium for investors.
                                  0
                                  • positive results just announced this will skyrocket soon
                                    0
                                    • huge buyers buying this, I'll follow the money
                                      0
                                      • with the mountain of cash the company has it will succeed in one of the treatments studied and then the price will go back 10-fold. key is to hang on now.
                                        0
                                        • We do not need to see the clinical trial results as a failure. Drugs made with IFX-1 are not better than conventional drugs, but not worse. It means, it is time to pioneer a new clinical pipeline using the clinical trial results.
                                          0
                                          • Yeah their pipeline still has several other things plus their platform flexible to try other approaches. After this set back lessons learnt to succeed in the other ones
                                            0
                                            • Buy this stock for good mid term returns. Institutions too quick on the sell call
                                              0
                                              • How to have a market cap of 99 million when only the cash in bank is over 120 mil? this one will bounce back hard
                                                0
                                                • 78 m now. I also think it is exaggerated. But the market is right and if it wants to go to under 10 millions, it will.
                                                  0
                                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.